Article
A leucine-rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls.
Clinical and translational science - 1 Aug 2023
Vissers Maurits F J M, Troyer Matthew D, Thijssen Eva, Pereira Diana R, Heuberger Jules A A C, Groeneveld Geert Jan, Huntwork-Rodriguez Sarah
Abstract excerpt
Increased leucine-rich repeat kinase 2 (LRRK2) kinase activity is an established risk factor for Parkinson's disease (PD), and several LRRK2 kinase inhibitors are in clinical development as potential novel disease-modifying therapeutics. This biomarker characterization study explored within- and between-subject variability of multiple LRRK2 pathway biomarkers (total LRRK2 [tLRRK2], phosphorylation of the serine...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.